PMID- 24061469
OWN - NLM
STAT- MEDLINE
DCOM- 20140320
LR  - 20220330
IS  - 1998-4774 (Electronic)
IS  - 0019-509X (Linking)
VI  - 50
IP  - 3
DP  - 2013 Jul-Sep
TI  - Clinico-pathological impact of cytogenetic subgroups in B-cell chronic 
      lymphocytic leukemia: experience from India.
PG  - 261-7
LID - 10.4103/0019-509X.118730 [doi]
AB  - BACKGROUND: The present study of 238 B-cell Chronic Lymphocytic Leukemia (B-CLL) 
      patients were undertaken to seek the prevalence and to evaluate 
      clinico-pathological significance of recurrent genetic abnormalities such as 
      del(13q14.3), trisomy 12, del(11q22.3) (ATM), TP53 deletion, del(6q21) and IgH 
      translocation/deletion. MATERIALS AND METHODS: We applied interphase - 
      fluorescence in situ hybridization (FISH) on total 238 cases of B-CLL. RESULTS: 
      Our study disclosed 69% of patients with genetic aberrations such as 13q deletion 
      (63%), trisomy 12 (28%), 11q deletion (18%), 6q21 deletion (11%) with 
      comparatively higher frequency of TP53 deletion (22%). Deletion 13q displayed as 
      a most frequent sole abnormality. In group with coexistence of >/=2 aberrations, 
      13q deletion was a major clone indicating del(13q) as a primary event followed by 
      11q deletion, TP53 deletion, trisomy 12, 6q deletion as secondary progressive 
      events. In comparison with del(13q), trisomy 12, group with coexistence of >/=2 
      aberrations associated with poor risk factors such as hyperleukocytosis, advanced 
      stage, and multiple nodes involvement. In a separate study of 116 patients, 
      analysis of IgH abnormalities revealed either partial deletion (24%) or 
      translocation (5%) and were associated with del(13q), trisomy 12, TP53 and ATM 
      deletion. Two of 7 cases had t(14;18), one case had t(8;14), and four cases had 
      other variant IgH translocation t(?;14). CONCLUSION: Detail characterization and 
      clinical impact are necessary to ensure that IgH translocation positive CLL is a 
      distinct pathological entity. Our data suggests that CLL with various cytogenetic 
      subsets, group with coexistence of >/=2 aberrations seems to be a complex 
      cytogenetic subset, needs more attention to understand biological significance 
      and to seek clinical impact for better management of disease.
FAU - Amare, P S Kadam
AU  - Amare PS
AD  - Cancer Cytogenetics Laboratory, Tata Memorial Hospital, Parel, Mumbai, 
      Maharashtra, India.
FAU - Gadage, V
AU  - Gadage V
FAU - Jain, H
AU  - Jain H
FAU - Nikalje, S
AU  - Nikalje S
FAU - Manju, S
AU  - Manju S
FAU - Mittal, N
AU  - Mittal N
FAU - Gujral, S
AU  - Gujral S
FAU - Nair, R
AU  - Nair R
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Cancer
JT  - Indian journal of cancer
JID - 0112040
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chromosome Aberrations
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - India
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics/*pathology
MH  - Male
MH  - Middle Aged
MH  - Young Adult
EDAT- 2013/09/26 06:00
MHDA- 2014/03/22 06:00
CRDT- 2013/09/25 06:00
PHST- 2013/09/25 06:00 [entrez]
PHST- 2013/09/26 06:00 [pubmed]
PHST- 2014/03/22 06:00 [medline]
AID - IndianJournalofCancer_2013_50_3_261_118730 [pii]
AID - 10.4103/0019-509X.118730 [doi]
PST - ppublish
SO  - Indian J Cancer. 2013 Jul-Sep;50(3):261-7. doi: 10.4103/0019-509X.118730.